Sage Therapeutics, Inc.
NASDAQ:SAGE
6.32 (USD) • At close November 7, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 86.455 | 7.686 | 6.308 | 1,114.2 | 6.868 | 90.273 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 2.159 | 0.813 | 0.553 | 0.565 | 0.4 | 1.1 | 0.5 | 0.281 | 0.115 | 0 | 0 | 0 |
| Gross Profit
| 84.296 | 6.873 | 5.755 | 1,113.635 | 6.468 | 89.173 | -0.5 | -0.281 | -0.115 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.975 | 0.894 | 0.912 | 0.999 | 0.942 | 0.988 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 356.235 | 326.163 | 283.166 | 292.714 | 368.815 | 282.107 | 210.277 | 120.756 | 69.357 | 24.1 | 14.357 | 7.229 |
| General & Administrative Expenses
| 274.524 | 227.699 | 183.498 | 196.952 | 345.777 | 201.404 | 62.878 | 39.407 | 25.293 | 9.71 | 3.381 | 2.402 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 44.598 | 11.176 | 5.268 | 3.076 | 0 | 0 | 0 |
| SG&A
| 274.524 | 227.699 | 183.498 | 196.952 | 345.777 | 201.404 | 62.878 | 39.407 | 25.293 | 9.71 | 3.381 | 2.402 |
| Other Expenses
| -0.383 | 0.015 | 0.134 | 0.25 | 0.082 | 0.022 | -0.064 | -0.035 | -0.023 | -0.009 | -0.003 | -0.001 |
| Operating Expenses
| 630.759 | 553.862 | 466.664 | 489.666 | 714.592 | 483.511 | 273.155 | 160.163 | 94.65 | 33.81 | 18.279 | 9.631 |
| Operating Income
| -579.849 | -546.989 | -460.909 | 596.226 | -708.124 | -393.238 | -273.155 | -160.163 | -94.65 | -33.81 | -18.279 | -9.631 |
| Operating Income Ratio
| -6.707 | -71.167 | -73.067 | 0.535 | -103.105 | -4.356 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -33.769 | 14.205 | 3.017 | 9.847 | 27.886 | 0.022 | -0.064 | -0.035 | -0.023 | -0.009 | -0.002 | -0.001 |
| Income Before Tax
| -541.489 | -532.784 | -457.892 | 606.073 | -680.238 | -372.882 | -270.12 | -158.987 | -94.495 | -33.811 | -18.281 | -9.632 |
| Income Before Tax Ratio
| -6.263 | -69.319 | -72.589 | 0.544 | -99.045 | -4.131 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| -5.357 | -29.517 | -7.065 | 15.516 | -30.087 | 20.356 | -3.63 | -1.492 | -0.293 | -0.059 | 0.002 | 0 |
| Net Income
| -541.489 | -503.267 | -450.827 | 606.073 | -650.151 | -372.882 | -270.12 | -158.987 | -94.495 | -33.811 | -18.281 | -9.632 |
| Net Income Ratio
| -6.263 | -65.478 | -71.469 | 0.544 | -94.664 | -4.131 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -9.05 | -8.49 | -7.68 | 11.66 | -12.79 | -8.08 | -7.09 | -4.75 | -3.4 | -1.57 | -1.09 | -0.57 |
| EPS Diluted
| -9.05 | -8.49 | -7.68 | 11.43 | -12.79 | -8.08 | -7.09 | -4.75 | -3.4 | -1.57 | -0.73 | -0.39 |
| EBITDA
| -511.684 | -546.989 | -460.909 | 651.712 | -708.124 | -393.238 | -273.155 | -160.163 | -94.65 | -33.81 | -18.232 | -9.587 |
| EBITDA Ratio
| -5.919 | -71.167 | -73.067 | 0.585 | -103.105 | -4.356 | 0 | 0 | 0 | 0 | 0 | 0 |